HomeCompareAGE vs VYM

AGE vs VYM: Dividend Comparison 2026

AGE yields 18.02% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGE wins by $36.8K in total portfolio value
10 years
AGE
AGE
● Live price
18.02%
Share price
$11.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.6K
Annual income
$5,421.64
Full AGE calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — AGE vs VYM

📍 AGE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGEVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGE + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGE pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGE
Annual income on $10K today (after 15% tax)
$1,531.53/yr
After 10yr DRIP, annual income (after tax)
$4,608.39/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, AGE beats the other by $4,371.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGE + VYM for your $10,000?

AGE: 50%VYM: 50%
100% VYM50/50100% AGE
Portfolio after 10yr
$46.2K
Annual income
$2,850.09/yr
Blended yield
6.17%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGE buys
0
VYM buys
1
PoliticianChamberTickerTypeAmountDate
Carol Devine Miller🏢 House$VYM▲ Buy$15,001 - $50,0002022-11-02
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGEVYM
Forward yield18.02%2.41%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$64.6K$27.8K
Annual income after 10y$5,421.64$278.55
Total dividends collected$34.8K$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: AGE vs VYM ($10,000, DRIP)

YearAGE PortfolioAGE Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$12,502$1,801.80$11,151$241.44+$1.4KAGE
2$15,482$2,105.21$12,413$246.79+$3.1KAGE
3$19,002$2,436.52$13,794$251.79+$5.2KAGE
4$23,127$2,794.89$15,306$256.47+$7.8KAGE
5$27,925$3,179.07$16,960$260.84+$11.0KAGE
6$33,468$3,587.47$18,768$264.92+$14.7KAGE
7$39,829$4,018.19$20,745$268.71+$19.1KAGE
8$47,086$4,469.06$22,905$272.24+$24.2KAGE
9$55,319$4,937.71$25,265$275.51+$30.1KAGE
10$64,613$5,421.64$27,842$278.55+$36.8KAGE

AGE vs VYM: Complete Analysis 2026

AGEStock

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Full AGE Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this AGE vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGE vs SCHDAGE vs JEPIAGE vs OAGE vs KOAGE vs MAINAGE vs VIGAGE vs DGROAGE vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.